Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation

被引：1

作者：

Sun, Xin ^{[1
]}

Chen, Wenjuan ^{[1
]}

Qu, Xiujuan ^{[1
,2
,3
,4
]}

Chen, Ying ^{[1
,2
,3
,4
]}

机构：

[1] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang, Peoples R China

[2] China Med Univ, Key Lab Anticanc Drugs & Biotherapy Liaoning Prov, Hosp 1, Shenyang, Peoples R China

[3] Liaoning Prov Clin Res Ctr Canc, Shenyang, Peoples R China

[4] China Med Univ, Key Lab Precis Diag & Treatment Gastrointestinal T, Minist Educ, Hosp 1, Shenyang, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

关键词：

cutaneous squamous cell carcinoma; PARPi; fluzoparib; BRCA2 germline mutation; case report; BREAST-CANCER; VARIANTS; DIAGNOSIS; THERAPY; PLACEBO;

D O I：

10.3389/fphar.2022.968060

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Poly ADP-ribose polymerase inhibitors (PARPis) are widely used for patients with BRCA1/2 mutations. However, until now, there is no available evidence reported for the efficiency of PARPis in cutaneous squamous cell carcinoma (cSCC). Case presentation: We presented a case of a 40-year-old man diagnosed with metastatic cSCC, relapsing after multiple lines of chemotherapy. Liquid biopsy detected a BRCA2 pathogenic germline mutation (c.3109C > T), indicating PARPis might be effective for this patient. The patient achieved tumor stability, and progression-free survival was five months without severe adverse effects after taking fluzoparib. Conclusion: This result confirmed that PARPis were effective for metastatic cSCC patients with germline BRCA2 pathogenic mutations and provided a new treatment option for this group of patients.

引用

页数：7

共 33 条

[1] Characterization of Metastatic Urothelial Carcinoma via Comprehensive Genomic Profiling of Circulating Tumor DNA [J].

Agarwal, Neeraj ;

Pal, Sumanta K. ;

Hahn, Andrew W. ;

Nussenzveig, Roberto H. ;

Pond, Gregory R. ;

Gupta, Sumati V. ;

Wang, Jue ;

Bilen, Mehmet A. ;

Naik, Gurudatta ;

Ghatalia, Pooja ;

Hoimes, Christopher J. ;

Gopalakrishnan, Dharmesh ;

Barata, Pedro C. ;

Drakaki, Alexandra ;

Faltas, Bishoy M. ;

Kiedrowski, Lesli A. ;

Lanman, Richard B. ;

Nagy, Rebecca J. ;

Vogelzang, Nicholas J. ;

Boucher, Kenneth M. ;

Vaishampayan, Ulka N. ;

Sonpavde, Guru ;

Grivas, Petros .

CANCER, 2018, 124 (10) :2115-2124

[2] Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study [J].

Azribi, Fathi ;

Abdou, Ehab ;

Dawoud, Emad ;

Ashour, Mohamed ;

Kamal, Amgad ;

Al Sayed, Mohamed ;

Burney, Ikram .

BMC CANCER, 2021, 21 (01)

[3] Characterization of BRCA1 and BRCA2 Deleterious Mutations and Variants of Unknown Clinical Significance in Unilateral and Bilateral Breast Cancer: The WECARE Study [J].

Borg, Ake ;

Haile, Robert W. ;

Malone, Kathleen E. ;

Capanu, Marinela ;

Diep, Ahn ;

Torngren, Therese ;

Teraoka, Sharon ;

Begg, Colin B. ;

Thomas, Duncan C. ;

Concannon, Patrick ;

Mellemkjaer, Lene ;

Bernstein, Leslie ;

Tellhed, Lina ;

Xue, Shanyan ;

Olson, Eric R. ;

Liang, Xiaolin ;

Dolle, Jessica ;

Borresen-Dale, Anne-Lise ;

Bernstein, Jonine L. .

HUMAN MUTATION, 2010, 31 (03) :E1200-E1240

[4] Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology [J].

Boussios, Stergios ;

Rassy, Elie ;

Shah, Sidrah ;

Ioannidou, Evangelia ;

Sheriff, Matin ;

Pavlidis, Nicholas .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (05) :329-333

[5] Melanoma of unknown primary: New perspectives for an old story [J].

Boussios, Stergios ;

Rassy, Elie ;

Samartzis, Eleftherios ;

Moschetta, Michele ;

Sheriff, Matin ;

Alejandro Perez-Fidalgo, Jose ;

Pavlidis, Nicholas .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 158

[6] Cancer Susceptibility Mutations in Patients With Urothelial Malignancies [J].

Carlo, Maria I. ;

Ravichandran, Vignesh ;

Srinavasan, Preethi ;

Bandlamudi, Chaitanya ;

Kemel, Yelena ;

Ceyhan-Birsoy, Ozge ;

Mukherjee, Semanti ;

Mandelker, Diana ;

Chaim, Joshua ;

Knezevic, Andrea ;

Rana, Satshil ;

Fnu, Zarina ;

Breen, Kelsey ;

Arnold, Angela G. ;

Khurram, Aliya ;

Tkachuk, Kaitlyn ;

Cipolla, Catharine K. ;

Regazzi, Ashley ;

Hakimi, A. Ari ;

Al-Ahmadie, Hikmat ;

Dalbagni, Guido ;

Cadoo, Karen A. ;

Walsh, Michael F. ;

Teo, Min-Yuen ;

Funt, Samuel A. ;

Coleman, Jonathan A. ;

Bochner, Bernard H. ;

Iyer, Gopa ;

Solit, David B. ;

Stadler, Zsofia K. ;

Zhang, Liying ;

Rosenberg, Jonathan E. ;

Taylor, Barry S. ;

Robson, Mark E. ;

Berger, Michael F. ;

Vijai, Joseph ;

Bajorin, Dean F. ;

Offit, Kenneth .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)

[7] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Coleman, Robert L. ;

Oza, Amit M. ;

Lorusso, Domenico ;

Aghajanian, Carol ;

Oaknin, Ana ;

Dean, Andrew ;

Colombo, Nicoletta ;

Weberpals, Johanne, I ;

Clamp, Andrew ;

Scambia, Giovanni ;

Leary, Alexandra ;

Holloway, Robert W. ;

Amenedo Gancedo, Margarita ;

Fong, Peter C. ;

Goh, Jeffrey C. ;

O'Malley, David M. ;

Armstrong, Deborah K. ;

Garcia-Donas, Jesus ;

Swisher, Elizabeth M. ;

Floquet, Anne ;

Konecny, Gottfried E. ;

McNeish, lain A. ;

Scott, Clare L. ;

Cameron, Terri ;

Maloney, Lara ;

Isaacson, Jeff ;

Goble, Sandra ;

Grace, Caroline ;

Harding, Thomas C. ;

Raponi, Mitch ;

Sun, James ;

Lin, Kevin K. ;

Giordano, Heidi ;

Ledermann, Jonathan A. .

LANCET, 2017, 390 (10106) :1949-1961

[8] European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022 [J].

Garbe, Claus ;

Amaral, Teresa ;

Peris, Ketty ;

Hauschild, Axel ;

Arenberger, Petr ;

Basset-Seguin, Nicole ;

Bastholt, Lars ;

Bataille, Veronique ;

Del Marmol, Veronique ;

Dreno, Brigitte ;

Fargnoli, Maria C. ;

Forsea, Ana-Maria ;

Grob, Jean-Jacques ;

Holler, Christoph ;

Kaufmann, Roland ;

Kelleners-Smeets, Nicole ;

Lallas, Aimilios ;

Lebbe, Celeste ;

Lytvynenko, Bohdan ;

Malvehy, Josep ;

Moreno-Ramirez, David ;

Nathan, Paul ;

Pellacani, Giovanni ;

Saiag, Philippe ;

Stratigos, Alexander J. ;

Van Akkooi, Alexander C. J. ;

Vieira, Ricardo ;

Zalaudek, Iris ;

Lorigan, Paul .

EUROPEAN JOURNAL OF CANCER, 2022, 170 :236-255

[9] Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic [J].

Ghose, Aruni ;

Moschetta, Michele ;

Pappas-Gogos, George ;

Sheriff, Matin ;

Boussios, Stergios .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)

[10] Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study [J].

Han, H. S. ;

Dieras, V. ;

Robson, M. ;

Palacova, M. ;

Marcom, P. K. ;

Jager, A. ;

Bondarenko, I. ;

Citrin, D. ;

Campone, M. ;

Telli, M. L. ;

Domchek, S. M. ;

Friedlander, M. ;

Kaufman, B. ;

Garber, J. E. ;

Shparyk, Y. ;

Chmielowska, E. ;

Jakobsen, E. H. ;

Kaklamani, V. ;

Gradishar, W. ;

Ratajczak, C. K. ;

Nickner, C. ;

Qin, Q. ;

Qian, J. ;

Shepherd, S. P. ;

Isakoff, S. J. ;

Puhalla, S. .

ANNALS OF ONCOLOGY, 2018, 29 (01) :154-161

← 1 2 3 4 →